SYNARC Announces Alliance with Stanford CCAL to Expand Cardiovascular Offering

Newark, CA – November 22, 2013 - Synarc, the world's leading imaging core lab dedicated to clinical trials, and the Stanford Cardiovascular Core Analysis Lab (CCAL), an innovator in advanced cardiovascular clinical trials imaging, have signed an alliance agreement to jointly provide imaging services for clinical trials. The agreement extends to cardiovascular drug and device trials with the aim of improving sponsor clinical trial services. Synarc and the Stanford CCAL together will provide a seamless service offering to sponsors for clinical trial imaging services supporting cardiovascular drug and medical device trials.

According to Dr. Peter Fitzgerald, MD, PhD, and Dr. Yasu Honda, MD, the directors of the Stanford's CCAL, the Stanford / Synarc alliance will offer many advantages for sponsors. Dr. Fitzgerald comments "Combining the innovation and advanced imaging analysis capabilities of the Stanford CCAL with the global site support and technology platform of Synarc will improve the quality of imaging services available for cardiovascular drug and medical device clinical trials". Per Dr. Honda, "Our combined effort will provide a more comprehensive teaching program for young researchers at Stanford and help to facilitate rapid and precise analysis of new technologies for patients with cardiovascular diseases". Also, per Dr. Thomas Fuerst, PhD, a founder and the Chief Science Officer of Synarc, this alliance "will beneficially expand imaging core lab product offerings by combining Stanford's advanced cardiovascular imaging capabilities and vast experience with Synarc's robust, compliant Project and Data management yielding a superior level of service."

The Stanford CCAL / Synarc alliance will also feature enhanced training opportunities for Stanford CCAL fellowship training in clinical trials management as the participants share personnel, training, and other resources. The partnership will combine two innovative, veteran organizations with strong scientific resources and traditions. This will result in unmatched combined offerings retaining innovation and experience while adding capacity for scalability and global reach. This seamless, comprehensive service offering to sponsors promises to accelerate and improve clinical trials to enhance innovation and patient care outcomes.
About Stanford CCAL

THE CENTER FOR CARDIOVASCULAR TECHNOLOGY

The Stanford Center for Cardiovascular Technology was founded by Dr. Peter Fitzgerald and Dr. Paul Yock in the mid-1990s for development and testing of new diagnostic and therapeutic technologies in cardiovascular medicine.

The Center's focus includes early-stage concepts for new cardiovascular technologies, providing a clearinghouse where these ideas can be refined and tested in animal models and clinical studies. CCAL resides within this center.

CARDIOVASCULAR CORE ANALYSIS LABORATORY (CCAL)

Using Intravascular Ultrasound (IVUS) and other advanced imaging techniques such as OCT, Magnetic Resonance and CT, Core Laboratory Services are provided for both US and international research studies and clinical trials.

As part of the cardiovascular training program at Stanford, this clinical research unit, known as Cardiovascular Core Analysis Laboratory (CCAL), utilizes a number of fellows and post-doctorates who are eager to work on scientifically challenging projects. Research from the CCAL has led to over 350 peer-reviewed or invited articles. Dr. Yasu Honda, MD, directs the academic mission of CCAL and is a director.

About Synarc

Synarc is the world's premier imaging core lab. At our centers in the United States, Europe, and Asia, we provide our clients with the industry's highest quality of service across modalities and therapeutic areas. Through our state-of-the-art, FDA-compliant software systems, our radiologists and experts efficiently perform quantitative and qualitative assessments of images from clinical sites around the world. For more information, please visit www.synarc.com.